Real-World Evidence of Efficacy and Safety of Levonadifloxacin (Oral and IV) in the Management of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Findings of a Retrospective, Multi-Center Study

Background Antimicrobial resistance by bacteria poses a substantial threat to the success in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Levonadifloxacin is a novel benzoquinolizine subclass of quinolone which has a broad spectrum of activity, available in both oral...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Kapil D, Sharma, Jai B, Anand, Ashok, Reddy N, Pavan K, Kadam, Pramod, Debnath, Khokan, Bhapkar, Sandeep, Thampi, Bini M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Family/General Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121184/
https://www.ncbi.nlm.nih.gov/pubmed/35602817
http://dx.doi.org/10.7759/cureus.24299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121184/
https://www.ncbi.nlm.nih.gov/pubmed/35602817
http://dx.doi.org/10.7759/cureus.24299

Ejemplares similares